Cyclopentanohydrophenanthrene Ring System Patents (Class 536/5)
  • Patent number: 10294265
    Abstract: The subject disclosure is directed to functionalized bile acids, preparation thereof, and usage thereof for therapeutic and material applications. In one embodiment, a method of generating functionalized bile acid materials can comprise directly activating a carboxylic acid of a bile acid compound using a coupling agent comprising an amide or ester compound, thereby generating an intermediate bile acid derivative material. The method can further comprise attaching a functional group material to the intermediate bile acid derivative material by reacting the functional group material and the intermediate bile acid derivative material, thereby generating a functionalized bile acid material.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: May 21, 2019
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: James L. Hedrick, Nathaniel H. Park
  • Patent number: 10125331
    Abstract: Processes are described for refining a renewable oil. The processes may include the steps of adding one or more compounds to the renewable oil to produce a soap stock in the renewable oil, and separating at least a portion of the soap stock from the renewable oil. The processes may further include adding a polymer to the separated renewable oil to produce a refined renewable oil.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: November 13, 2018
    Assignee: Advanced Energy Development
    Inventors: Trevor G. Morgan, Tom Vytlacil, Colby Neeley, Charles Devlin
  • Patent number: 9745338
    Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 29, 2017
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Patent number: 9670245
    Abstract: Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal form L, crystal form M, crystal form N, and crystal form O are involved.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: June 6, 2017
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Guobin Ren, Changliang Dai, Jinyao Chen, Feng Chen, Minghui Qi, Wenming Zhu, Minghuang Hong, Hua Bai
  • Patent number: 9643992
    Abstract: Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: May 9, 2017
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Guobin Ren, Changliang Dai, Jinyao Chen, Feng Chen, Minghui Qi, Wenming Zhu, Minghuang Hong, Hua Bai
  • Patent number: 9598502
    Abstract: The present invention relates to a method of manufacturing ultra-low viscosity hydroxyalkyl cellulose through a partial neutralization method, and the method includes: reacting cellulose with an alkalizing agent to obtain alkalized cellulose; reacting the alkalized cellulose with an etherifying agent to obtain hydroxyalkyl cellulose; performing first neutralization of the hydroxyalkyl cellulose; decomposing the hydroxyalkyl cellulose by using hydrogen peroxide; and performing second neutralization of the hydroxyalkyl cellulose. Through the aforementioned method, ultra-low viscosity hydroxyalkyl cellulose can be manufactured while preventing a process problem, such as swelling, which may occur through the decomposition of an acid treatment.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: March 21, 2017
    Assignee: LOTTE FINE CHEMICAL CO., LTD.
    Inventors: Ji Hun Park, Yong Sung Jang, Myeong Ho Jeon
  • Patent number: 9115166
    Abstract: Exemplary embodiments of this invention encompass a method for degrading rebaudioside A and the rebaudioside A derivative products derived therefrom. In particular, this invention relates to a method for degrading rebaudioside A compositions to obtain rebaudioside A derivative products suitable for use as sweetener compositions.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: August 25, 2015
    Assignee: The Coca-Cola Company
    Inventors: Indra Prakash, Grant E. DuBois, Rafael I. San Miguel, John Clos
  • Patent number: 9079845
    Abstract: The disclosed invention refers to a process for obtaining fatty acid alkyl esters, rosin acids and sterols from crude tall oil (CTO), which is characterized by the following steps: (a) reacting the free fatty acids present in the CTO with lower alcohols; (b) esterifying the sterols in the CTO with boric acid or transesterifying the sterols with a catalyst; (c) separating the fatty acid lower alkyl esters and rosin acids from the remaining sterol borate esters or sterol esters of fatty acids to produce a stream of sterol esters; (d) separating the fatty acid alkyl esters from the rosin acids to produce a first stream of fatty acid alky esters and a second stream of rosin acids; and (e) converting the sterol esters into the free sterols to produce a third stream of free sterols.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: July 14, 2015
    Assignee: Cognis IP Management GmbH
    Inventors: Setsuo Sato, Henrique Jorge Sousa Sales, Hercules Peloggia, Peter Kempers, Sabine Both, Ulrich Schoerken, Thomas Wolf
  • Publication number: 20150112048
    Abstract: The present invention provides novel ginsenoside derivative compounds and the use thereof in protection against ischemia/reperfusion injury.
    Type: Application
    Filed: October 17, 2013
    Publication date: April 23, 2015
    Applicant: Macau University of Science and Tehnology
    Inventors: Jingrong WANG, Pei LUO, Hua ZHOU, Wai In CHAN, Liang LIU, Zhihong JIANG
  • Publication number: 20150111843
    Abstract: Disclosed herein are novel oxetane derivatives of avicin D, including compounds of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising these derivative compounds. Methods and intermediates useful for making the derivatives, and methods of using the derivatives and compositions thereof, including for the treatment of cancer, are also provided.
    Type: Application
    Filed: February 22, 2013
    Publication date: April 23, 2015
    Inventors: Valsala HARIDAS, Jordan GUTTERMAN, David L. PARKER
  • Patent number: 9012611
    Abstract: The present invention relates to the use of 3,8,12,14,17,20-oxo-substituted pregnene glycosides having the following formula I in the preparation of healthcare products, food additives and drugs for losing body weight, controlling body weight and inhibiting appetite of human beings or animals, wherein, R1 is a saccharide group, and R2 is an acyl group.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: April 21, 2015
    Assignee: Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Weimin Zhao, Shuangzhu Liu, Zhenhua Chen, Luoyi Wang
  • Publication number: 20150105543
    Abstract: The present invention provides an improved synthesis of a class of steroid saponins. Furthermore, the present invention provides a method of selectively discriminating between the C2 and C3 hydroxyl groups of a mono-glycosylated steroid saponin—a key step in the preparation of this class of compounds. Additionally, the present invention provides a range of steroid saponin derivatives, and methods of making them.
    Type: Application
    Filed: April 24, 2013
    Publication date: April 16, 2015
    Applicant: Oncology Research International Limited
    Inventors: Andrew Clive Muscroft-Taylor, Philip Andrew Marshall, Jennifer Mary Mason, David Millar Walker
  • Publication number: 20150099870
    Abstract: Provided are methods for the preparation of glycosylation products, including those represented by formula I: Sugar-O—R???I comprising the step of combining R?—OH, a glycosyl sulfide glycosyl donor (“thioglycoside donor”), a hypervalent iodine alkyl-transfer activating reagent, and a base. In an embodiment, the hypervalent iodine alkyl-transfer activating reagent is (phenyl(trifluoroethyl)iodonium triflimide).
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Clay S. Bennett, An-Hsiang A. Chu
  • Publication number: 20150057440
    Abstract: Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.
    Type: Application
    Filed: April 1, 2013
    Publication date: February 26, 2015
    Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Guobin Ren, Changliang Dai, Jinyao Chen, Feng Chen, Minghui Qi, Wenming Zhu, Minghuang Hong, Hua Bai
  • Publication number: 20150011739
    Abstract: The invention provides tandem facial amphiphiles for biochemical manipulations and characterization of membrane proteins, such as intrinsic membrane proteins. Members of this new family display favorable behavior with several membrane proteins. These amphiphiles can form relatively small micelles, and small changes in amphiphile chemical structures can result in large changes in their physical properties. The tandem facial amphiphiles can be used to aid the solubilization, isolation, purification, stabilization, crystallization, and/or structural determination of membrane proteins.
    Type: Application
    Filed: July 22, 2014
    Publication date: January 8, 2015
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Pil Seok Chae, Samuel Helmer GELLMAN
  • Patent number: 8889840
    Abstract: The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions (TJs) between vascular cells, thereby inhibiting vascular leakage. The vascular leakage inhibitor of the present disclosure has the activity of not only reducing vascular permeability but also recovering the integrity of damaged blood vessels. Accordingly, the vascular leakage inhibitor of the present disclosure can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present disclosure is synthesized from commercially available or easily synthesizable cholesterols, it has remarkably superior feasibility of commercial synthesis.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: November 18, 2014
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Young-Guen Kwon, Young-Ger Suh
  • Patent number: 8889841
    Abstract: The present invention is a method for purifying Rebaudioside C by subjecting “waste material,” generated during the Rebaudioside A manufacturing process, to liquid-liquid extraction and recrystallizing the Rebaudioside C.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: November 18, 2014
    Assignee: International Flavors & Fragrances Inc.
    Inventors: Zhen Chen, Ajay Pratap Singh
  • Publication number: 20140316120
    Abstract: Provided is a novel hair growth and hair restoration material having excellent efficacy in hair growth and hair restoration for both men and women, even when the components thereof are at ultra-dilute concentrations; the hair growth and hair restoration material being characterized in containing a steryl glucopyranoside, preferably a cholesteryl glucopyranoside, represented by general formula (I). (In the formula, Z represents a sterol residue from which the hydroxyl group attached to the 3-position of a cyclopentanohydrophenanthrene ring has been removed.
    Type: Application
    Filed: May 30, 2012
    Publication date: October 23, 2014
    Applicant: INSTITUTE OF RHEOLOGICAL FUNCTION OF FOOD CO., LTD.
    Inventors: Takehiko Fujino, Osami Nada, Yoshitaka Nadachi, Gunki Funatsu
  • Publication number: 20140255317
    Abstract: Provided is a compound represented by the general formula (1) (where: G represents a hexose-6-phosphate residue; and L represents a divalent linker group).
    Type: Application
    Filed: September 5, 2012
    Publication date: September 11, 2014
    Applicant: KYOTO UNIVERSITY
    Inventors: Keita Un, Mitsuru Hashida, Shigeru Kawakami, Makoto Kiso, Akiharu Ueki, Hiromune Ando
  • Publication number: 20140256660
    Abstract: The present invention describes novel single drug entities, formed by the linkage of an antibiotic with a steroidal drug via a linker. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
  • Patent number: 8815263
    Abstract: The invention provides tandem facial amphiphiles for biochemical manipulations and characterization of membrane proteins, such as intrinsic membrane proteins. Members of this new family display favorable behavior with several membrane proteins. These amphiphiles can form relatively small micelles, and small changes in amphiphile chemical structures can result in large changes in their physical properties. The tandem facial amphiphiles can be used to aid the solubilization, isolation, purification, stabilization, crystallization, and/or structural determination of membrane proteins.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: August 26, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Pil Seok Chae, Samuel Helmer Gellman
  • Publication number: 20140221633
    Abstract: The present invention provides a one-pot method of preparing an unprotected ?-O-glycolipid. The first step involves contacting a protected ?-iodo sugar with a catalyst and a lipid comprising a hydroxy group, under conditions sufficient to prepare a protected ?-O-glycolipid. The second step involves deprotecting the protected ?-O-glycolipid under conditions sufficient to prepare the unprotected ?-O-glycolipid, wherein the contacting and deprotecting steps are performed in a single vessel. The present invention also provides a one-pot method of preparing an unprotected ?-O-glycolipid following the steps for the preparation of the unprotected ?-O-glycolipid.
    Type: Application
    Filed: January 6, 2014
    Publication date: August 7, 2014
    Inventors: Jacquelyn Gervay-Hague, Wenjun Du, Suvarn S. Kulkarni, Matthew Schombs
  • Publication number: 20140187499
    Abstract: The invention relates to substituted anionic compounds consisting of a backbone made up of a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycosidic bonds, said saccharide units being chosen from the group consisting of pentoses, hexoses, uronic acids, N-acetylhexosamines in cyclic form or in open reduced form, which are randomly substituted. It also relates to the process for the preparation thereof and to the pharmaceutical compositions comprising same.
    Type: Application
    Filed: November 13, 2013
    Publication date: July 3, 2014
    Inventors: Gérard SOULA, Emmanuel DAUTY, Richard CHARVET
  • Patent number: 8765695
    Abstract: The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: December 25, 2007
    Date of Patent: July 1, 2014
    Assignees: Jecui Health Industry Corp. Ltd., Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Juntian Zhang, Shifeng Chu
  • Patent number: 8765696
    Abstract: A steroid compound of the Formula (1): [wherein R1 represents a group selected from the group consisting of H, CH3, C2H5, C3H7 and CH (CH3)2, R2 represents a group selected from NH2, NHAc and OCOR1, R3 represents a group selected from the group consisting of CH3, COOCH3 and CH2OCOR1.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: July 1, 2014
    Assignee: Mikasa Seiyaku Co., Ltd.
    Inventor: Takayuki Ishii
  • Publication number: 20140179761
    Abstract: The present invention provides targeting lipids of structure L100-linker-L101??(CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.
    Type: Application
    Filed: October 22, 2013
    Publication date: June 26, 2014
    Applicant: Tekmira Pharmaceuticals Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Narayanannair, Muthusamy Jayaraman
  • Patent number: 8759304
    Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: June 24, 2014
    Assignee: Telomerase Activation Science, Inc.
    Inventors: Calvin Bruce Harley, Allison C. Chin, Tsutomu Akama, Nancy Yuk-yu Ip, Yung-hou Wong, David M. Miller-Martini
  • Publication number: 20140170083
    Abstract: The invention relates to triterpenes and triterpene glycosides of the formula (I) and/or physiologically acceptable salts thereof, preferably naturally occurring triterpenes and triterpene glycosides from Mycetia balansae and/or physiologically acceptable salts thereof and orally consumable formulations comprising one or a plurality of these triterpenes and triterpene glycosides and/or physiologically acceptable salts thereof. The invention further relates to the use of these triterpenes and triterpene glycosides and/or physiologically acceptable salts thereof, preferably an extract of Mycetia balansae, for generating a sweet impression in an orally consumable formulation or for reinforcing the sweet impression of an orally consumable formulation comprising at least one further, preferably naturally occurring, sweet-tasting substance.
    Type: Application
    Filed: June 1, 2012
    Publication date: June 19, 2014
    Applicant: Symrise AG
    Inventors: Jakob Ley, Katharina Reichelt, Katja Obst, Ludger wessjohann, Sabine Wessjohann, Tran Van Sung, The Anh Nguyen, Ngo Van Trai
  • Publication number: 20140135278
    Abstract: The present invention relates to a novel compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers.
    Type: Application
    Filed: September 30, 2013
    Publication date: May 15, 2014
    Applicant: Macau University of Science and Technology
    Inventors: Liang LIU, Liping BAI, Hang DONG, Kam Wai WONG, Zhihong JIANG, Hua ZHOU
  • Publication number: 20140128582
    Abstract: The present invention provides a continuous preparation method of ginseng ginsenosides and polysaccharides, whereby the ginseng extract liquor and supercritical solvent are poured continuously into a separation tank at 10-30 MPa and 40-60° C. as well as a preset flow rate; so the ginseng extract liquor can be separated in the separation tank to obtain ginseng ginsenosides and polysaccharides at different positions of the separation tank.
    Type: Application
    Filed: November 6, 2012
    Publication date: May 8, 2014
    Inventors: Zer-Ran Yu, Be-Jen Wang
  • Publication number: 20140112975
    Abstract: L-Rhamnose antigen-lipid conjugates for recruitment of the immune system to sites of tumor growth for initiating an anti-tumor antigen response. Methods for introducing L-rhamnose antigen-conjugated lipids into cell membranes such that L-rhamnose antigens are displayed on the cell surface. The cells can be tumor cells and more specifically can be melanoma cells. Cells are contacted with one or more L-rhamnose antigen-lipid conjugates such that L-rhamnose antigen-lipid conjugates are inserted into the cell membrane. The cells can be contacted for example by intratumoral injection. Pharmaceutical compositions containing the L-rhamnose antigen-lipid conjugates and therapeutic methods employing the conjugates and compositions.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 24, 2014
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventor: WISCONSIN ALUMNI RESEARCH FOUNDATION
  • Patent number: 8703224
    Abstract: Thermally stable anhydrous Rebaudioside D can be provided by methods disclosed here and has been found to be more soluble in aqueous solutions than the previously known non-anhydrous Rebaudioside D. This physical property makes the anhydrous Reb D amenable to food and beverage manufacturing applications for which the non-anhydrous form is not suitable. Anhydrous Rebaudioside D is useful in sweeteners, and can be included in food and beverage products, which are also disclosed.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: April 22, 2014
    Assignee: PepsiCo, Inc.
    Inventor: Thomas Lee
  • Patent number: 8703723
    Abstract: The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: April 22, 2014
    Assignee: Centrose, LLC
    Inventor: Jill Hutchinson-Bollettieri
  • Patent number: 8674087
    Abstract: The present disclosure relates to processes useful in the isolation and purification of enfumafungin, which is classified as a triterpene glycoside antifungal compound and acts as a glucan synthase inhibitor. Enfumafungin has application in the treatment of conditions caused by fungal infection and is also useful as an intermediate in the preparation of other compounds useful as antifungal agents and/or inhibitors of (1,3)-?-D-glucan synthesis.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: March 18, 2014
    Assignee: Scynexis, Inc.
    Inventors: Jennifer M. Pollard, Rebecca A. Chmielowski, Lisa M. Dietrich, Francis P. Gailliot, Kent Goklen
  • Publication number: 20140066391
    Abstract: Steroid compounds are disclosed that have a formula represented by the following: and wherein m, n, t, u1, u2, v1, v2, R1a, R1b, R2a, R2b, R3a, R3b, R3c, R3d, and Y are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the treatment or prevention of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.
    Type: Application
    Filed: November 28, 2011
    Publication date: March 6, 2014
    Inventors: Dan R. Littman, Jun R. Huh, Nicolas Gabriel Albert Manel, Michael R. Krout, Daniel A. Ryan
  • Publication number: 20140058074
    Abstract: The present invention relates to the use of 3,8,12,14,17,20-oxo-substituted pregnene glycosides having the following formula I in the preparation of healthcare products, food additives and drugs for losing body weight, controlling body weight and inhibiting appetite of human beings or animals, wherein, R1 is a saccharide group, and R2 is an acyl group.
    Type: Application
    Filed: November 7, 2011
    Publication date: February 27, 2014
    Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Weimin Zhao, Shuangzhu Liu, Zhenhua Chen, Luoyi Wang
  • Patent number: 8648180
    Abstract: Smilaxchinoside F compound and its separation method are disclosed. The compound has the structure as following. The use of Smilaxchinoside F in the manufacture of a medicine for treating abnormal angiogenesis and its relating diseases is also disclosed.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: February 11, 2014
    Assignee: Guilin Sanjin Pharmaceuticals Co., Ltd.
    Inventor: Jieming Zou
  • Publication number: 20140039170
    Abstract: Beneficial effects are obtained by topically applying ginsenoside F2 to the skin to improve skin conditions, improve water content on the skin surface and related benefits improving skin problems associated with acne or atopy, providing a skin whitening effect, helping control of sebaceous secretion, tightening skin pores, or improving skin complexion through enhanced blood circulation, but also to improve scalp and hair conditions, such as providing an anti-dandruff effect, promoting hair growth, or preventing generation of grey hair.
    Type: Application
    Filed: July 5, 2013
    Publication date: February 6, 2014
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Kwon Real RYU, Dong Hyun KIM, Ok Chan LEE, Hyun Hee KIM, Myeong Hun YEOM, Jun Cheol CHO
  • Publication number: 20140017675
    Abstract: Provided is a ultra-high-sensitivity assay in which the assay can be made on a commonly used assay apparatus such as an absorptiometer and a plate reader or with naked eyes. The high-sensitivity assay in which the assay can be made on a commonly used assay apparatus or with naked eyes can be provided by combining an enzyme cycling method using thio-NAD(P) as a coenzyme, a labeling enzyme and a substrate for the labeling enzyme optimally, and by amplifying thio-NAD(P)H, which is a signaling substance, exponentially and then quantifying the thio-NAD(P)H colorimetrically.
    Type: Application
    Filed: March 23, 2012
    Publication date: January 16, 2014
    Inventor: Etsuro Ito
  • Publication number: 20140005132
    Abstract: The invention provides compounds of formula I, II, III, or IV: wherein R1 to R11, X, and Y have any of the values defined in the specification. The compounds inhibit Na, K-ATPase ?4 and are useful as contraceptive agents.
    Type: Application
    Filed: July 1, 2013
    Publication date: January 2, 2014
    Applicants: REGENTS OF THE UNIVERSITY OF MINNESOTA, THE UNIVERSITY OF KANSAS
    Inventors: Gustavo Blanco, Gunda I. Georg, Shameem Sultana Syeda
  • Publication number: 20140004499
    Abstract: The invention relates to methods of localizing biofunctional moieties (F) to surfaces and synthetic constructs of the general structure F-S-S? for use in such methods. F is the biofunctional moiety, S is a spacer covalently linking F to S?, and S? is sterol. In particular, the invention relates to the preparation of biofunctional surfaces and surface modified biological structures including cells (kodecytes), enveloped viruses (kodevirions) and liposomes or virosomes (kodesomes).
    Type: Application
    Filed: January 6, 2012
    Publication date: January 2, 2014
    Inventors: Nicolai Vladimirovich Bovin, Andrey Alfredovich Formanovsky, Stephen Micheal Henry, Stephen Robert Parker, Inna Stanislavovna Popova
  • Publication number: 20130303466
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
    Type: Application
    Filed: October 18, 2011
    Publication date: November 14, 2013
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Alain D. Baron
  • Publication number: 20130281387
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
    Type: Application
    Filed: October 18, 2011
    Publication date: October 24, 2013
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
  • Publication number: 20130266656
    Abstract: Bringing membrane proteins into aqueous solution generally requires the use of detergents or other amphiphilic agents. The invention provides a new class of amphiphiles, each of which includes a multi-fused ring system as a lipophilic group. These new amphiphiles confer enhanced stability to a range of membrane proteins in solution relative to conventional detergents, leading to improved structural and functional stability of membrane proteins, including integral membrane proteins. Accordingly, the invention provides new amphiphiles for biochemical manipulations and characterization of membrane proteins. These amphiphiles display favorable behavior with membrane proteins and can be used to aid the solubilization, isolation, purification, stabilization, crystallization, and/or structural determination of membrane proteins.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 10, 2013
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Samuel Helmer Gellman, Pil Seok Chae, Brian Kobilka, Soren Rasmussen
  • Patent number: 8552161
    Abstract: This invention relates to novel saponin compounds of formula II wherein MBz denotes p-methoxybenzoyl, and R is selected from the group comprising C6-10 aryl, C6-10 aryl-C1-4 alkyl-, C1-18 alkanoyl, C3-18 alkenyl, C6-10 aryl-C(O)—, C6-10 aryl-C1-4 alkyl-C(O)—, wherein each of the groups can optionally be substituted. These compounds possess a selective cytostatic activity, useful, e.g., in the treatment of proliferative diseases. The invention further relates to methods of preparation of the novel compounds and to a pharmaceutical composition containing these compounds.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: October 8, 2013
    Assignees: Uniwersytet W Bialymstoku, Univerzita Palackeho V Olomouci, Bioapex, S.R.O.
    Inventors: Jacek Witold Morzycki, Agnieszka Wojtkielewicz, Jana Oklestkova, Lucie Hoffmannova, Miroslav Strnad
  • Publication number: 20130210752
    Abstract: Methods of screening, identifying and isolating HMG-CoAR inhibitors are disclosed herein. In particular, said method is useful for screening natural raw products. The present invention also provides potent HMG-CoAR inhibitors for treatment and prevention of diseases and conditions associated with elevated cholesterol and/or blood lipid levels.
    Type: Application
    Filed: February 8, 2013
    Publication date: August 15, 2013
    Applicant: HONG KONG BAPTIST UNIVERSITY
    Inventor: Hong Kong Baptist University
  • Patent number: 8487090
    Abstract: A preparation of a kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution containing ginsenoside Rg3 0.5˜10 mg/ml: add 0.1-5% of ginsenoside solution to 0.1˜30% of adjuvant A, B{circle around (1)}{circle around (2)}{circle around (5)} at the temperature of 40˜100° C., the ratio of these two is 1:1˜300, add water after the solvent is recycled under reduced pressure; another kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution contains 0.1˜2 mg/ml of 20(R) of the ginsenoside Rg3, the preparation: add 0.1˜5% of ginsenoside solution to 20˜65% of adjuvant B{circle around (3)}{circle around (4)} at the temperature of 60˜100° C., main material to adjuvant B=1:100˜400, add water after the solvent is recycled under reduced pressure.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: July 16, 2013
    Assignee: Dalian Fusheng Natural Medicine Development Co., Ltd.
    Inventors: Li Fu, Qi Lu
  • Publication number: 20130178431
    Abstract: The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same.
    Type: Application
    Filed: December 27, 2012
    Publication date: July 11, 2013
    Applicants: CENTROSE, LLC
    Inventor: Jill Hutchinson-Bollettieri
  • Patent number: 8440632
    Abstract: Provided herein are ginsenoside compositions comprising at least 10% (w/w) of a protopanaxadiol type of ginsenoside suitable for administration to a subject. Also provided are methods using the ginsenoside compositions for reducing acetaldehyde concentrations, preventing or ameliorating a symptom of elevated acetaldehyde concentration, or reducing the risk of diseases or disorders caused by the intake of ethyl alcohol.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: May 14, 2013
    Assignee: Raptor Therapeutics Inc.
    Inventors: Thomas E. Daley, Michael Tempesta
  • Publication number: 20130115251
    Abstract: The invention provides tandem facial amphiphiles for biochemical manipulations and characterization of membrane proteins, such as intrinsic membrane proteins. Members of this new family display favorable behavior with several membrane proteins. These amphiphiles can form relatively small micelles, and small changes in amphiphile chemical structures can result in large changes in their physical properties. The tandem facial amphiphiles can be used to aid the solubilization, isolation, purification, stabilization, crystallization, and/or structural determination of membrane proteins.
    Type: Application
    Filed: November 5, 2012
    Publication date: May 9, 2013
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventor: Wisconsin Alumni Research Foundation